Prasugrel loading — Competitive Intelligence Brief

Prasugrel loading (Prasugrel loading) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: P2Y12 receptor antagonist (thienopyridine). Area: Cardiovascular.

marketed P2Y12 receptor antagonist (thienopyridine) P2Y12 receptor Cardiovascular Small molecule

Target snapshot

Prasugrel loading (Prasugrel loading) — Azienda Policlinico Umberto I. Prasugrel is a thienopyridine antiplatelet agent that irreversibly inhibits the P2Y12 adenosine diphosphate receptor on platelets, preventing platelet aggregation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Prasugrel loading TARGET	Prasugrel loading	Azienda Policlinico Umberto I	marketed	P2Y12 receptor antagonist (thienopyridine)	P2Y12 receptor
Switch ticagrelor to clopidogrel	Switch ticagrelor to clopidogrel	The First Affiliated Hospital with Nanjing Medical University	marketed	P2Y12 receptor antagonist; antiplatelet agent	P2Y12 receptor
OAC + clopicogrel	OAC + clopicogrel	St. Antonius Hospital	marketed	Anticoagulant + antiplatelet agent combination	Coagulation cascade (OAC) and P2Y12 receptor (clopidogrel)
bivalirudin + clopidogrel + aspirin	bivalirudin + clopidogrel + aspirin	Centre Hospitalier de PAU	marketed	Anticoagulant + antiplatelet combination	Thrombin (Factor IIa), P2Y12 receptor, cyclooxygenase
Aspirin combined with clopidogrel	Aspirin combined with clopidogrel	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	marketed	Dual antiplatelet agent	Cyclooxygenase (COX) and P2Y12 receptor
ASA plus Clopidogrel	ASA plus Clopidogrel	Texas Cardiac Arrhythmia Research Foundation	marketed	Dual antiplatelet agent	COX-1 (aspirin); P2Y12 receptor (clopidogrel)
Aspirin and Clopidogrel	Aspirin and Clopidogrel	Assistance Publique - Hôpitaux de Paris	marketed	Antiplatelet agent (dual therapy)	Cyclooxygenase (COX) and P2Y12 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (P2Y12 receptor antagonist (thienopyridine) class)

1. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
2. Azienda Policlinico Umberto I · 1 drug in this class
3. Deutsches Herzzentrum Muenchen · 1 drug in this class
4. Elliot Israel, MD · 1 drug in this class
5. Research Maatschap Cardiologen Rotterdam Zuid · 1 drug in this class
6. Sanofi · 1 drug in this class